# Phase 2b Study of GSK4532990 in Adults With NASH

> **NCT05583344** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 284 (actual)

## Conditions studied

- Nonalcoholic Fatty Liver Disease
- Non-alcoholic Fatty Liver Disease

## Interventions

- **DRUG:** GSK4532990
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05583344
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-01-02
- **Primary completion:** 2026-01-31
- **Final completion:** 2027-04-05
- **Target enrollment:** 284 (ACTUAL)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05583344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05583344, "Phase 2b Study of GSK4532990 in Adults With NASH". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05583344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*